Company & Sponsor Intelligence

Sanofi

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials6

Recruiting2

Completed2

Countries2

Therapeutic footprint

alzheimersepilepsymultiple_sclerosisneuroimmunologyneuromuscular

Indexed studies

NCT04879628Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis
multiple_sclerosis · United StatesPHASE2

NCT00104013Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
alzheimers · United StatesPHASE3

NCT02667496Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
alzheimers · United StatesPHASE2

NCT05132569Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis
neuromuscular · United StatesPHASE3

NCT06714448A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia
epilepsy · FranceCOMPLETED

NCT06290128A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
neuroimmunology · United StatesPHASE3

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →